mitoxantrone / Generic mfg. - LARVOL DELTA

RNA functional modulation by Mitoxantrone via RNA structural ensemble repartitioning. (PubMed, Nat Commun) - "Transcriptome-wide chemical probing in human cells revealed preferential binding to GC-rich structured regions, although only a subset showed structural change. Furthermore, global analysis of 5' UTR ensembles showed altered structural heterogeneity and translation, demonstrating functional repartitioning of RNA conformational landscapes."

Journal • Oncology

Mitoxantrone restores tigecycline activity by inhibiting tet(X4) and disrupting resistance mechanisms in Escherichia coli (ESCMID Global 2026) - No abstract available

Mitoxantrone restores tigecycline activity by inhibiting tet(X4) and disrupting resistance mechanisms in Escherichia coli (ESCMID Global 2026) - No abstract available

LONG-TERM FOLLOW-UP OF PREDOMINANTLY ASIAN PATIENTS WITH RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA TREATED WITH GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY IN THE PHASE 3 COMMODORE TRIAL (EHA 2025) - P3 | "In this phase III, open-label, multicenter study, patients with R/R FLT3mut+ AML from 48 sites in China, Malaysia, Thailand, Singapore and Russia, were randomized 1:1 to gilteritinib (120 mg/day) or SC (low-dose cytarabine; mitoxantrone, etoposide, and intermediate-dose cytarabine; or fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor). With a median follow-up of over 3 years, gilteritinib improved clinical outcomes compared with SC and was well-tolerated in a predominantly Asian population with R/R FLT3mut+ AML, consistent with the results from the primary analysis, further supporting its long-term use."

Clinical • P3 data • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • FLT3

Real-world effectiveness of systemic therapies after 177Lu]Lu-PSMA-617 (177Lu-PSMA-617) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis. (ASCO-GU 2026) - "Systemic therapies included ARPIs (abiraterone, enzalutamide, darolutamide, apalutamide); chemotherapy (cabazitaxel, docetaxel, carboplatin, cisplatin, etoposide, mitoxantrone); immunotherapy (pembrolizumab, sipuleucel-T); poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, talazoparib, rucaparib); and radium-223. In this real-world analysis, meaningful clinical responses were observed in a subset of patients who received subsequent systemic therapies after 177Lu-PSMA-617."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Reflections on prevention and treatment of post-thyroidectomy hypoparathyroidism: current management approaches and future prospects. (PubMed, Front Endocrinol (Lausanne)) - "Moreover, methodologies for the precise recognition and preservation (naked eye, near-infrared autofluorescence, indocyanine green, carbon nanoparticles, and mitoxantrone hydrochloride) of the parathyroid gland during thyroid surgery have been explored, along with recent therapeutic innovations (palopegteriparatide and parathyroid organoids). Finally, this review prospects and interventions via organoids are contemplated. The aim of the literature is to recapitulate the knowledge and the gaps in this field, increasing awareness of postoperative hypoparathyroidism, and improve the prognosis for patients afflicted with hypoparathyroidism."

Journal • Review • Endocrine Disorders • Hypoparathyroidism

Sodium chloride nanoparticles as urinary bladder cancer therapeutics (AACR 2026) - "While several strategies have been developed to target ion homeostasis as potential anticancer agents, including channel blockers and ionophores, the sodium chloride nanoparticle strategy may offer additional advantages in the context of cancer therapy.Immunogenic cell death (ICD) is a unique form of regulated cell death that promotes an anti-tumor immune response and contributes to the success of several cancer therapies such as cisplatin and mitoxantrone (MTX). Finally, we evaluated the therapeutic efficacy of PSCNPs in subcutaneous tumor models, both as a single treatment and in combination with αPD1. Our results suggest that PSCNPs hold promise as a novel and effective treatment for bladder cancer, with the potential to boost immunity and transform the tumor microenvironment without causing systemic toxicity."

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CALR • HMGB1

VENETOCLAX PLUS HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM-VEN) AS BRIDGE TO OR SALVAGE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY AML (EBMT 2026) - P1/2 | "Our real-world analysis confirms HAM/VEN as save and efficient salvage treatment for R/R AML facilitating a bridge to transplant in a high rate of patients with an encouraging posttransplant outcome including patients after second transplantation."

Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation

SUCCESSFUL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOBLASTIC LEUKEMIA FOLLOWING A HIGHLY EFFICIENT REGIMEN, FLAG-MITOXANTRONE WITH LOW-DOSE 7 DAYS VENETOCLAX (EBMT 2026) - "Background: FLAG (G-CSF, Fludarabine, Cytarabine) combined with either Idarubicin (Ida) or Mitoxantrone (Mitox) are effective and well tolerated in newly diagnosed (ND) or relapsed/refractory (R/R) Acute Myeloblastic Leukemia (AML)(Burnett et al...FLAG-Mitox +Ven combined G-CSF (5μg/kg/d) on d1-7, Fludarabine (30mg/m2/d IV), and Cytarabine (1.5g/m2/d IV) on d2-5, Mitox (12mg/m2/d IV) d2,4 and Ven (100mg PO daily) given with voriconazole d2-8...Among the 50 R/R pts, first induction therapy consisted of 7+3 regimen in 32 pts (64%), FLAG-Ida in 15 pts (30%) and 5-Azacytidine+Ven in 3 pts (6%)... FLAG–Mitox+Ven (7d) is a highly-effective and well-tolerated for remission induction and MRD negativity in ND and R/R AML pts. High survival outcomes were demonstrated across ELN 2022 risk groups in ND AML pts. This regimen is also an effective bridge to AHSCT."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • Transplantation • FLT3

Real-World Pharmacovigilance Analysis of Drug-Induced Decreased Cardiac Ejection Function: Evidence from the FAERS Database (2004-2024). (PubMed, Curr Cardiol Rev) - "This large-scale real-world analysis identifies both established and novel DCEF risk signals, highlights heterogeneity in onset timing, and emphasizes the predominance of antineoplastic agents. Clinically, these findings suggest the need for periodic echocardiographic monitoring of left ventricular ejection fraction, particularly in patients receiving high-risk drugs such as mitoxantrone, trastuzumab, doxorubicin, and pertuzumab. Early-phase monitoring is crucial for "early-failure" agents, while extended follow-up is warranted for drugs with delayed toxicity, such as doxorubicin. These results provide actionable evidence to support individualized risk management and regulatory label updates."

Adverse events • Journal • Real-world evidence • Cardiovascular • Oncology

SUCCESSFUL MANAGEMENT OF POST-TRANSPLANT AML RELAPSE WITH SALVAGE CHEMOTHERAPY AND DONOR LYMPHOCYTE INFUSION (EBMT 2026) - "Complete remission was achieved after induction chemotherapy with 3+7 (idarubicin, cytarabine (ara-C)). Following consolidation with high-dose ara-C, the patient underwent sibling-matched allogeneic HCT with a myeloablative conditioning regimen (busulfan/fludarabine/ATG). Methotrexate, ATG, and cyclosporine were administered as graft-versus-host disease (GvHD) prophylaxis...HAM (high-dose ara-C, mitoxantrone) chemotherapy was administered due to relapse of AML after transplantation...If a mutation is identified through genetic testing, targeted therapies or venetoclax can be combined... The prognosis for patients with relapsed AML after allogeneic SCT is poor, with a two-year overall survival rate below 20%. There is no established standard treatment for relapse post-transplantation. To reduce tumor burden, intensive chemotherapy is recommended for fit patients, while low-intensity chemotherapy or hypomethylating agents are suggested for unfit patients."

IO biomarker • Post-transplantation • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Transplantation • FLT3 • TP53

VENETOCLAX PLUS HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM-VEN) AS BRIDGE TO OR SALVAGE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY AML (EBMT 2026) - P1/2 | "Our real-world analysis confirms HAM/VEN as save and efficient salvage treatment for R/R AML facilitating a bridge to transplant in a high rate of patients with an encouraging posttransplant outcome including patients after second transplantation."

Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation

SUCCESSFUL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOBLASTIC LEUKEMIA FOLLOWING A HIGHLY EFFICIENT REGIMEN, FLAG-MITOXANTRONE WITH LOW-DOSE 7 DAYS VENETOCLAX (EBMT 2026) - "Background: FLAG (G-CSF, Fludarabine, Cytarabine) combined with either Idarubicin (Ida) or Mitoxantrone (Mitox) are effective and well tolerated in newly diagnosed (ND) or relapsed/refractory (R/R) Acute Myeloblastic Leukemia (AML)(Burnett et al...FLAG-Mitox +Ven combined G-CSF (5μg/kg/d) on d1-7, Fludarabine (30mg/m2/d IV), and Cytarabine (1.5g/m2/d IV) on d2-5, Mitox (12mg/m2/d IV) d2,4 and Ven (100mg PO daily) given with voriconazole d2-8...Among the 50 R/R pts, first induction therapy consisted of 7+3 regimen in 32 pts (64%), FLAG-Ida in 15 pts (30%) and 5-Azacytidine+Ven in 3 pts (6%)... FLAG–Mitox+Ven (7d) is a highly-effective and well-tolerated for remission induction and MRD negativity in ND and R/R AML pts. High survival outcomes were demonstrated across ELN 2022 risk groups in ND AML pts. This regimen is also an effective bridge to AHSCT."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • Transplantation • FLT3

PERSONALIZED THERAPY GUIDED BY EX VIVO DRUG RESPONSE PROFILING ENABLES ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RELAPSED/REFRACTORY ACUTE LEUKEMIA WITH IMMATURE PHENOTYPE (EBMT 2026) - "Treatment regimens were selected based on ex vivo drug sensitivity profiles: three patients received venetoclax plus bortezomib (VEBO), while one patient (pt#3) received VEBO plus mitoxantrone.At the time of transplantation, two patients (pt#2 and pt#4) had achieved complete remission (CR); notably, one of these patients (pt#2) had previously undergone allogeneic HSCT. Although limited to a small patient cohort, ex vivo drug screening platform successfully guided therapeutic option in R/R AL patients, with very high risk phenotype enabling successful bridging to allogeneic transplantation significantly reducing disease burden."

Preclinical • Bone Marrow Transplantation • Hematological Malignancies • Hepatology • Leukemia • Transplantation

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (clinicaltrials.gov) - P2 | N=22 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2029 ➔ May 2029 | Trial primary completion date: May 2027 ➔ Jan 2026

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • FLT3

RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (clinicaltrialsregister.eu) - P4 | N=289 | Recruiting | Sponsor: Medizinische Hochschule Hannover | N=128 ➔ 289

Enrollment change • Minimal residual disease • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (clinicaltrialsregister.eu) - P4 | N=128 | Recruiting | Sponsor: Medizinische Hochschule Hannover | N=52 ➔ 128

Enrollment change • Minimal residual disease • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial. (PubMed, Blood) - P3 | "Patients received low-dose cytarabine, mitoxantrone or idarubicin, and G-CSF (LDC) or standard-dose induction chemotherapy (SDC) (cytarabine, daunomycin, and etoposide). In conclusion, the LDC regimen was well tolerated and was associated with CR, EFS, and OS rates that were not inferior to those of patients treated with the SDC regimen. The trial was registered at Chinese Clinical Trial Registry (ChiCTR1800015883)."

Head-to-Head • Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Pediatrics • Transplantation

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. (PubMed, Blood) - P3 | "In total 281 patients with AML with poor response after first induction or untreated first relapse were randomized 1:1 to remission induction (RIST) with high-dose cytarabine plus mitoxantrone versus immediate alloHCT with sequential conditioning after non-intensive disease control measures (DisC) preferentially watchful waiting only. Well tolerable novel bridging therapies and post-transplant maintenance with targeted drugs are urgently warranted, especially for adverse-risk AML, to improve outcome after alloHCT. NCT02461537."

Journal • Acute Myelogenous Leukemia • Transplantation

IntReALL BCP 2020 International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 (clinicaltrialsregister.eu) - P2/3 | N=765 | Not yet recruiting | Sponsor: Charite Universitaetsmedizin Berlin KR

New P2/3 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

Comparative Efficacy of 35 Disease-modifying Therapies in Relapsing-remitting MS: A Network Meta-analysis Identifying Top Performers for Relapse, MRI Activity, and Disability Progression (AAN 2026) - "At 6 months, SC IFNbeta-1b (RR 0.14) and SC Ofatumumab (RR 0.33) were associated with the lowest disability progression... Alemtuzumab and the Ocrelizumab formulations were highly effective for relapse prevention, while Ponesimod + DMF and Natalizumab formulations reduced MRI lesions. Mitoxantrone was associated with long-term prevention of disability progression."

Retrospective data • CNS Disorders • Multiple Sclerosis

Integrating computational engines to identify TSPAN6 as a migrasome-associated target for immunotherapy sensitization. (PubMed, Front Immunol) - "Collectively, our findings establish TSPAN6 as a migrasome-related regulator driving adverse immunotherapy outcomes and responses. Targeting TSPAN6, potentially with mitoxantrone, presents a potential strategy to enhance immunotherapy efficacy."

IO biomarker • Journal • Oncology • LGALS9 • NECTIN2 • PD-L1 • TSPAN6

S00854: Serial cardiac magnetic resonance imaging (CMR) with contrast agents and biomarker analysis for the detection of cardiotoxicity nunder anthracycline-containing cancer therapy - A monocentric, low interventional Phase IV pilot study (clinicaltrialsregister.eu) - P4 | N=93 | Recruiting | Sponsor: Robert Bosch Gesellschaft fuer medizinische Forschung mbH | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Cardiovascular • Oncology

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial. (PubMed, Lancet Haematol) - P1/2 | "High-dose cytarabine and mitoxantrone plus venetoclax appeared to be safe, showed promising activity, and could be a new therapeutical approach for medically fit patients with relapsed or refractory acute myeloid leukaemia, especially as a bridge to allogeneic HCT."

Journal • P1/2 data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

AG120-221-C-001: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Agios Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • IDH1 • IDH2 • UGT1A1